Abstract: A form-fill-seal packing apparatus of the flow wrapper type accepts individuated items via in-feed conveyor. Items are moved through horizontal open lower-sided forming tube 10 by resting indirectly on an underneath transit conveyor, through the underside part of a continuous film bag forming from a supply of film around the forming tube, using a forming shoulder. The bag is longitudinally sealed beside the forming tube. Data may be printed on an upper film surface over a platen including an upper part of the forming tube. An outfeed conveyor carries transversely sealed wrapped items on to a vacuum sealer.

Abstract: A form-fill-seal packing apparatus of the flow wrapper type accepts individuated items via in-feed conveyor. Items are moved through horizontal open lower-sided forming tube 10 by resting indirectly on an underneath transit conveyor, through the underside part of a continuous film bag forming from a supply of film around the forming tube, using a forming shoulder. The bag is longitudinally sealed beside the forming tube. Data may be printed on an upper film surface over a platen including an upper part of the forming tube. An outfeed conveyor carries transversely sealed wrapped items on to a vacuum sealer.

Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Abstract: Methods and apparatus related to executing an online multimedia game. Some implementations are directed to a method for determining a matchup of two players, receiving multimedia selections from the players of the matchup, providing the selections to other players, and determining a winner of the matchup based on ratings provided by the other players. Some implementations are directed to prompting one player of the matchup for a multimedia subject for the multimedia selections and receiving either a multimedia subject or a deferral to the other player of the matchup for selection of a multimedia subject.

Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Abstract: Methods and apparatus related to executing an online multimedia game. Some implementations are directed to a method for determining a matchup of two players, receiving multimedia selections from the players of the matchup, providing the selections to other players, and determining a winner of the matchup based on ratings provided by the other players. Some implementations are directed to prompting one player of the matchup for a multimedia subject for the multimedia selections and receiving either a multimedia subject or a deferral to the other player of the matchup for selection of a multimedia subject.

Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Abstract: The invention relates to a method for determining the quantity of pre-synaptic neuromuscular blocking substance (notably botulinum toxin) contained in a sample. In one aspects, the method comprises the following steps: (i) determining the minimum voltage Vm needed to induce the contraction of muscle tissue, said muscle tissue being connected to an electrical stimulator through a motor nerve and preferably immersed in an oxygenated physiological buffer containing glucose; (ii) adding the sample containing the pre-synaptic neuromuscular blocking substance; (iii) electrically stimulating, at a voltage at least equal to Vm, the muscle tissue at certain time intervals; (iv) comparing the effect induced by the sample to the effect induced by a reference substance and thereby determining the quantity of the pre-synaptic neuromuscular blocking substance in the sample.

Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

Abstract: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPD.

Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are alleviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

Abstract: This invention relates to piperidine derivatives of formula I wherein R1, R2, R3 and R4 are as defined herein useful in the treatment of a variety of disorders, including those in which the modulation of CCR5 receptors is implicated. Disorders that may be treated or prevented by the present derivatives include HIV and genetically related retroviral infections (and the resulting acquired immune deficiency syndrome, AIDS), rheumatoid arthritis, solid organ transplant reject (graft vs. host disease), asthma and COPD.

Abstract: A porous matrix suitable for use as a tissue scaffold is described. The matrix may be shaped before insertion into or at the target tissue site, or injected via a minimally invasive method. The matrix may be pre-seeded with cells of the target tissue or may be used to support growth of the local endogenous tissue. The matrix may contain growth factors or other pharmacologically acceptable moieties such as antibiotics.

Abstract: Compounds represented by Formula I: which are useful as are alpha-1A/B adrenoceptor antagonists, to methods of treating conditions associated with the activity of alpha-1A/B adrenoceptors, and to methods of making said compounds, wherein Ar, Z, R, R?, R5 and R10 are as defined herein.

Abstract: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating diseases that are allieviated with CCR5 antagonists. The invention includes pharmaceutical compositions and methods of using the compounds for the treatment of these diseases. The invention further includes processes for the preparation of compounds according to formula I.

Abstract: This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X-Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Abstract: A packaging apparatus enables a product (300) to be scanned by scanning apparatus (302) and moved by a pivotal conveyor (122) onto a platen (103A), adjustable in size by a sizing apparatus (108), before the platen (103A) with the product (300) is moved into a bag (304) which has been opened out to a required extent by a bag holding means (109). The platen (103A) can then be inverted for the discharge of the bagged product (301) onto an exit conveyor (123).

Abstract: This invention relates to compounds which are generally alpha-1A/B adrenoceptor antagonists and which are represented by Formula I: wherein Z is —C(O)— or —S(O)2—, X is carbon or nitrogen, Y is carbon, and X—Y considered together are two adjoining atoms of the ring A, said ring being a fused aromatic ring of five to six atoms per ring optionally incorporating one to two heteroatoms per ring, chosen from N, O, or S; and the other substituents are as defined in the specification; or individual isomers, racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and methods of preparation thereof.

Abstract: A process for producing a metal article coated with a metal layer having a biaxially textured surface, which process comprises eletctrodepositing the metal layer on a biaxially textured metal substrate such that the surface of the metal layer has the same texture as that of the substrate.

Abstract: A bagging device (6) including at least two bag forming means (2, 3) capable of forming bags of a selected variable length from a supply of the material (4) from which the bags are to be formed, transporting means (7, 8, 10) to, in use convey item of differing dimensions to a selected position (5) or to one of a range of available selected positions, sizing means (15) to determine the size of each individual item, and production means to cause in use a bag of desired length to be formed by a selected one of said bag forming means (2, 3).